We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

53 hedge funds and large institutions have $389M invested in ArriVent BioPharma in 2024 Q1 according to their latest regulatory filings, with 53 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

68.37% more ownership

Funds ownership: 0% → 68.37% (+68%)

Holders
53
Holders Change
+53
Holders Change %
–
% of All Funds
0.76%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
53
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
+$79.3M
2
O
OrbiMed
New York
+$61.1M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$39.3M
4
OCA
Octagon Capital Advisors
New York
+$39.2M
5
SI
Sofinnova Investments
California
+$34.2M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HA
1
HHLR Advisors
Cayman Islands
$70.2M +$79.3M +3,929,117 New
O
2
OrbiMed
New York
$54.1M +$61.1M +3,027,328 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$34.8M +$39.3M +1,950,034 New
OCA
4
Octagon Capital Advisors
New York
$34.7M +$39.2M +1,943,836 New
SI
5
Sofinnova Investments
California
$30.3M +$34.2M +1,696,752 New
SCM
6
Suvretta Capital Management
New York
$27.9M +$31.5M +1,563,709 New
GCGM
7
General Catalyst Group Management
Massachusetts
$26.7M +$30.1M +1,494,786 New
NHAS
8
Novo Holdings A/S
Denmark
$19.2M +$21.7M +1,077,140 New
BlackRock
9
BlackRock
New York
$11.7M +$13.2M +654,804 New
Vanguard Group
10
Vanguard Group
Pennsylvania
$11.6M +$13.1M +648,735 New
HH
11
HSG Holding
Hong Kong
$10.5M +$13.4M +663,308 New
ACP
12
Altitude Crest Partners
Connecticut
$9.92M +$11.2M +555,555 New
CAM
13
Cormorant Asset Management
Massachusetts
$9.2M +$10.4M +515,000 New
PA
14
Perceptive Advisors
New York
$7.41M +$8.37M +415,000 New
Citadel Advisors
15
Citadel Advisors
Florida
$5.12M +$5.78M +286,512 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$4.02M +$4.54M +225,049 New
Millennium Management
17
Millennium Management
New York
$3.78M +$4.27M +211,689 New
FCM
18
Farallon Capital Management
California
$2.71M +$3.06M +151,768 New
State Street
19
State Street
Massachusetts
$2.18M +$2.47M +122,264 New
WP
20
Woodline Partners
California
$1.79M +$2.02M +100,000 New
AA
21
AlphaCentric Advisors
Puerto Rico
$1.48M +$1.67M +83,000 New
Northern Trust
22
Northern Trust
Illinois
$1.4M +$1.58M +78,409 New
Charles Schwab
23
Charles Schwab
California
$1.39M +$1.57M +77,760 New
GCM
24
Ghisallo Capital Management
Massachusetts
$893K +$1.01M +50,000 New
Jane Street
25
Jane Street
New York
$660K +$745K +36,959 New
1
2 3

AVBP Hedge Fund Activity: Q1 2024 in Review

53 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q1 2024, worth a combined $389M.

Buyers outnumbered sellers: 53 funds opened new AVBP positions and 0 closed out — a net gain of 53 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was HHLR Advisors, opening a new position worth an estimated $79.3M.

  • 53 institutional investors held ArriVent BioPharma (AVBP) as of Q1 2024, up from 0 in Q4 2023.
  • Funds reported $389M of ArriVent BioPharma stock for Q1 2024.
  • 53 funds opened new ArriVent BioPharma positions in Q1 2024 and 0 closed out, a net change of +53 holders.
  • The largest ArriVent BioPharma buyer in Q1 2024 was HHLR Advisors, an estimated $79.3M added.

Based on aggregated 13F filings for Q1 2024.